Cargando…

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Manapov, Farkhad, Kenndoff, Saskia, Käsmann, Lukas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073737/ https://www.ncbi.nlm.nih.gov/pubmed/35529786 http://dx.doi.org/10.21037/tlcr-21-950

Ejemplares similares

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis
por: Flörsch, Benedikt, et al.
Publicado: (2022)

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
por: Käsmann, Lukas, et al.
Publicado: (2023)

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study
por: Käsmann, Lukas, et al.
Publicado: (2023)

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
por: Taugner, Julian, et al.
Publicado: (2021)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study
por: Käsmann, Lukas, et al.
Publicado: (2022)

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
por: Jabbour, Salma K., et al.
Publicado: (2021)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
por: Taugner, Julian, et al.
Publicado: (2021)

Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis
por: Karin, Monika, et al.
Publicado: (2020)

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer
por: Käsmann, Lukas, et al.
Publicado: (2019)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
por: Taugner, Julian, et al.
Publicado: (2021)

Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer
por: Taugner, Julian, et al.
Publicado: (2020)

In regards to Chu et al.: Patterns of brain metastasis immediately before prophylactic cranial irradiation (PCI): implications for PCI optimization in limited-stage small cell lung cancer
por: Käsmann, Lukas, et al.
Publicado: (2020)

Positron Emission Tomography/Computed Tomography (PET/CT)-Based, Local Consolidative Radiotherapy after Chemoimmunotherapy in Metastatic, Non-Oncogene-Addicted Non-Small-Cell Lung Cancer (NSCLC)
por: Angelini, Lucia, et al.
Publicado: (2023)

Combustion Performance of Spherical Propellants Deterred by Energetic Composite Deterring Agents
por: Liang, Hao, et al.
Publicado: (2021)

Keynotes
Publicado: (2023)

Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery
por: Eze, Chukwuka, et al.
Publicado: (2020)

799. A Pseudo-Outbreak of Pseudomonas fluorescens Infections
por: Jaber, Tariq, et al.
Publicado: (2021)

Nicolás Copérnico
por: Gortari, Elí de, 1918-1991
Publicado: (1975)

Nicolás Copérnico
Publicado: (1975)

Nicolás Guillén
por: Augier, Angel I., 1910-
Publicado: (1971)

Nicolae Grigorescu.
por: Grigorescu, Nicolae Ion, 1838-1907

Nicolás Guillén
por: David, Juan, 1911-1981

Nicolás Nickleby
por: Dickens, Charles, 1812-1870

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Nicolás : el surgimiento del Anticristo /
por: LaHaye, Tim F.
Publicado: (1999)

Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Gennen, Kathrin, et al.
Publicado: (2020)

Edition Eulenburg No. 799, Horn Concerto, : D major - Ré majeur - D dur KV 412 /

Timing of tumor-induced atelectasis resolution and pulmonary function restoration in the course of image-guided moderate hypofractionated thoracic irradiation: a case report and mini-review of literature
por: Bodensohn, Raphael, et al.
Publicado: (2021)

Radiation-Induced Lung Injury: Prevention, Diagnostics and Therapy in the Era of the COVID-19 Pandemic
por: Käsmann, Lukas, et al.
Publicado: (2022)

Designing Opioids That Deter Abuse
por: Raffa, Robert B., et al.
Publicado: (2012)

Nicolae Grigorescu : 1838-1907.

Keynote Address
por: Zinsou, Lionel
Publicado: (2019)

Keynote Address
por: Cherkaoui El Moursli, Rajaa
Publicado: (2019)

Keynote Address
por: Schönenberger, Klaus
Publicado: (2019)

Welcome & Keynote
por: Martin, Robert "Uncle Bob"
Publicado: (2019)

Keynote Address
por: Bordry, Frederick
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_16dlu66orq86ir14e6o8c6jmbq